Document Detail


Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study.
MedLine Citation:
PMID:  22183107     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
PURPOSE: The purpose of this pilot study was to assess whether outcome in metastatic or recurrent breast cancer patients is related to metabolic response to endocrine therapy determined by (18)F-FDG PET/CT. METHODS: The study group comprised 22 patients with breast cancer (age 58 ± 11 years, mean ± SD) who were scheduled to receive endocrine therapy. They were systematically assessed by PET/CT at baseline and after a mean of 10 ± 4 weeks for evaluation of response after induction. All patients demonstrated FDG-avid lesions on the baseline PET/CT scan. The metabolic response was assessed according to EORTC criteria and based on the mean difference in SUV(max) between the two PET/CT scans, and the patients were classified into four groups: complete or partial metabolic response, or stable or progressive metabolic disease (CMR, PMR, SMD and PMD, respectively). All patients were followed in our institution. RESULTS: Metastatic sites were localized in bone (n = 15), lymph nodes (n = 11), chest wall (n = 3), breast (n = 5), lung (n = 3), soft tissue (n = 1) and liver (n = 1). PMR was observed in 11 patients (50%), SMD in 5 (23%) and PMD in 6 (27%). The median progression-free survival (PFS) times were 20, 27 and 6 months in the PMR, SMD and PMD groups, respectively. PFS in the SMD group differed from that in the PMR and SMD groups (p < 0.0001). CONCLUSION: Metabolic response assessed by FDG PET/CT imaging in patients with metastatic breast cancer treated with endocrine therapy is predictive of the patients' PFS.
Authors:
Nina Mortazavi-Jehanno; Anne-Laure Giraudet; Laurence Champion; Florence Lerebours; Elise Le Stanc; Veronique Edeline; Olivier Madar; Dominique Bellet; Alain Paul Pecking; Jean-Louis Alberini
Related Documents :
12821027 - 3d visualization, analysis, and treatment of the prostate using trans-urethral ultrasound.
18378527 - Early clinical evaluation of a novel three-dimensional structure delineation software t...
21047537 - Enhanced noscapine delivery using upar-targeted optical-mr imaging trackable nanopartic...
10757597 - Detection of internal organ movement in prostate cancer patients using portal images.
8863997 - A prospective study comparing the accuracy of the clinical diagnosis of meniscus tear w...
19152027 - A pilot study to assess the utility of spect/ct-based lymph node imaging to localize ly...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-12-20
Journal Detail:
Title:  European journal of nuclear medicine and molecular imaging     Volume:  -     ISSN:  1619-7089     ISO Abbreviation:  -     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101140988     Medline TA:  Eur J Nucl Med Mol Imaging     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Service de Médecine nucléaire, Institut Curie, Hôpital René Huguenin, 35 rue Dailly, 92210, Saint-Cloud, France, nina.jehanno@gmail.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Extracorporeal tourniquet method for intermittent hepatic pedicle clamping during laparoscopic liver...
Next Document:  Comparison of sequential planar (177)Lu-DOTA-TATE dosimetry scans with (68)Ga-DOTA-TATE PE...